×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NERV – minerva neurosciences, inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NERV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
02:18 am
nerv
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]
Low
Report
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia [Yahoo! Finance]
2/3
07:50 pm
nerv
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
Low
Report
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript [Seeking Alpha]
1/26
07:00 am
nerv
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Low
Report
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
11/25
01:54 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/19
08:30 am
nerv
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Low
Report
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
11/18
01:18 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
5/13/2025
07:30 am
nerv
minerva neurosciences, inc
BEAT
Report
-5.2%
minerva neurosciences, inc
2/25/2025
07:00 am
nerv
minerva neurosciences, inc
BEAT
Report
0.0%
minerva neurosciences, inc
2/25/2025
07:00 am
nerv
minerva neurosciences, inc
BEAT
Report
0.0%
minerva neurosciences, inc
2/25/2025
07:00 am
nerv
minerva neurosciences, inc
BEAT
Report
0.0%
minerva neurosciences, inc
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/5
02:51 pm
nerv
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
Medium
Report
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
2/3
09:00 am
nerv
Form 8-K Minerva Neurosciences, For: Feb 03
Medium
Report
Form 8-K Minerva Neurosciences, For: Feb 03
1/7
06:02 am
nerv
Form EFFECT Minerva Neurosciences,
Medium
Report
Form EFFECT Minerva Neurosciences,
1/6
04:53 pm
nerv
Form 424B3 Minerva Neurosciences,
Medium
Report
Form 424B3 Minerva Neurosciences,
12/31
04:30 pm
nerv
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Vivo Opportunity Fund Holdings, L.P.
Low
Report
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Vivo Opportunity Fund Holdings, L.P.
12/30
04:05 pm
nerv
Form SCHEDULE 13D/A Minerva Neurosciences, Filed by: Boehringer AG
Low
Report
Form SCHEDULE 13D/A Minerva Neurosciences, Filed by: Boehringer AG
12/29
04:05 pm
nerv
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
Low
Report
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
12/29
08:29 am
nerv
Form SCHEDULE 13G Minerva Neurosciences, Filed by: FEDERATED HERMES, INC.
Medium
Report
Form SCHEDULE 13G Minerva Neurosciences, Filed by: FEDERATED HERMES, INC.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/21
Form 4 Minerva Neurosciences, For: Jun 19 Filed by: Index Venture Associates IV Ltd
40.2%
3/13 Form 8-K Minerva Neurosciences, For: Mar 12 15.4%
4/27 Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020 10.6%
12/24 Investors flock to neuro drug makers after FDA approves new schizophrenia drug [MarketWatch] 9.4%
7/1 Form 4 Minerva Neurosciences, For: Jun 27 Filed by: DOYLE WILLIAM F 8.9%
8/5 Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates 8.1%
3/2 Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020 7.6%
12/10 Form SC 13G/A Minerva Neurosciences, Filed by: FEDERATED INVESTORS INC /PA/ 7.0%
7/9 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 6.4%
12/20 Minerva Neurosciences Inc (NASDAQ: NERV) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.5%
3/13 Form 8-K Minerva Neurosciences, For: Mar 12 15.4%
4/27 Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020 10.6%
12/24 Investors flock to neuro drug makers after FDA approves new schizophrenia drug [MarketWatch] 9.4%
7/1 Form 4 Minerva Neurosciences, For: Jun 27 Filed by: DOYLE WILLIAM F 8.9%
8/5 Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates 8.1%
3/2 Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020 7.6%
12/10 Form SC 13G/A Minerva Neurosciences, Filed by: FEDERATED INVESTORS INC /PA/ 7.0%
7/9 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 6.4%
12/20 Minerva Neurosciences Inc (NASDAQ: NERV) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.5%
TOP News Decliners
10/1
Minerva Neurosciences Announces Update for Three Clinical Trials
-28.4%
12/18 Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder -17.9%
10/1 Minerva Neurosciences Inc (NASDAQ: NERV) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock. -15.8%
6/24 UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals [MarketWatch] -15.3%
3/9 Minerva Neurosciences Inc (NASDAQ: NERV) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.6%
10/18 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.7%
1/17 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -7.7%
11/4 Q3/2019 9/30/2019 EPS -0.360 ZacksConsensus -0.370 ActVsEst 0.010 - Beat -7.2%
5/21 Form 4 Minerva Neurosciences, For: May 17 Filed by: Index Venture Associates V Ltd -6.9%
2/25 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.8%
12/18 Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder -17.9%
10/1 Minerva Neurosciences Inc (NASDAQ: NERV) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock. -15.8%
6/24 UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals [MarketWatch] -15.3%
3/9 Minerva Neurosciences Inc (NASDAQ: NERV) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.6%
10/18 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.7%
1/17 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -7.7%
11/4 Q3/2019 9/30/2019 EPS -0.360 ZacksConsensus -0.370 ActVsEst 0.010 - Beat -7.2%
5/21 Form 4 Minerva Neurosciences, For: May 17 Filed by: Index Venture Associates V Ltd -6.9%
2/25 Minerva Neurosciences Inc (NASDAQ: NERV) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: